SCHEMBL9942948

SCHEMBL9942948

CNC12CCC(COS(=O)(=O)c3ccc(C)cc3)(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.43
CYP2C9 P11712 1/20 0.40
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TP53 P04637 2/20 0.38
KCNE1 P15382 1/20 0.37
CCR1 P32246 1/20 0.37
KCNQ1 P51787 1/20 0.37
POLB P06746 1/20 0.37
LIPG Q9Y5X9 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MAPT P10636 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9942971 0.92 KCNH2 (0.35) KCNH2CYP2C9PKMTDP1TP53
SCHEMBL9942907 0.86 CYP2C9 (0.46) KCNH2CYP2C9ALDH1A1PKMTDP1
SCHEMBL9942888 0.86 POLB (0.35) TP53POLB
SCHEMBL9905172 0.83 KCNH2 (0.35) KCNH2CYP2C9MEN1KMT2A
SCHEMBL9943048 0.83 TP53 (0.35) ALDH1A1TP53POLBSMN1; SMN2KMT2A
SCHEMBL9942869 0.82 MMP13 (0.35) KCNH2CYP2C9PKMTDP1TP53
SCHEMBL9901046 0.82 CYP2C9 (0.37) KCNH2CYP2C9
SCHEMBL9942882 0.80 RORC (0.32) KCNH2CYP2C9ALDH1A1SMN1; SMN2MAPT
SCHEMBL9904915 0.78 CYP2C9 (0.38) KCNH2CYP2C9
SCHEMBL9904934 0.77 MMP13 (0.36) KCNH2CYP2C9PKMTDP1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
WO-2012078834-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309698-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885ALDH1A1 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.